Inflammatory Breast Cancer Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
Condition: Malignant Neoplasm of Breast Interventions: Drug: Cobimetinib; Drug: Atezolizumab; Drug: Eribulin Sponsors: M.D. Anderson Cancer Center; Genentech, Inc. Not yet recruiting - verified June 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2017 Category: Research Source Type: clinical trials
